Keith D. Dawkins

Showing 1-20 of 37 articles

Stable CAD

The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial

Milojevic M, Head S, Mack M, Mohr F, Morice M, Dawkins K, Holmes DR, Serruys P, Kappetein AP

May 20, 2018 | 10.4244/EIJ-D-17-00620

Impact of bioresorbable versus permanent polymer on long-term vessel wall inflammation and healing: a comparative drug-eluting stent experimental study

Wilson G, McGregor J, Conditt G, Shibuya M, Sushkova N, Eppihimer M, Hawley S, Rousselle S, Huibregtse B, Dawkins K, Granada J

February 20, 2018 | 10.4244/EIJ-D-17-00332

A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study

Han Y, Liu H, Yang Y, Zhang J, Xu K, Fu G, Su X, Jiang T, Pang W, Chen J, Yuan Z, Li H, Wang H, Hong T, Liu H, Sun F, Allocco D, Zhang M, Dawkins K

November 20, 2017 | 10.4244/EIJ-D-17-00271

Interventions for valvular disease

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01024

Interventions for valvular disease

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort

Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01025

Coronary interventions

Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?

Roy A, Chevalier B, Lefèvre T, Louvard Y, Segurado R, Sawaya F, Spaziano M, Neylon A, Serruys P, Dawkins K, Kappetein AP, Mohr F, Colombo A, Feldman T, Morice M

September 20, 2017 | 10.4244/EIJ-D-16-00991

Coronary interventions

Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy

Kereiakes D, Meredith I, Masotti M, Carrié D, Moreno R, Erglis A, Mehta S, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe R, Reitman A, Janssens L, Christen T, Dawkins K, Windecker S

March 20, 2017 | 10.4244/EIJ-D-16-00643

Peripheral interventions

Fluorocopolymer-coated nitinol self-expanding paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in a porcine iliofemoral model

Hou D, Huibregtse B, Eppihimer M, Stoffregen W, Kocur G, Hitzman C, Stejskal E, Heil J, Dawkins K

August 20, 2016 | 10.4244/EIJV12I6A128

Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study

Watkins S, Oldroyd K, Preda I, Holmes DR, Colombo A, Morice M, Leadley K, Dawkins K, Mohr F, Serruys P, Feldman T

April 20, 2015 | 10.4244/EIJV10I12A244

One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE)

Tamburino C, Capodanno D, Erglis A, Menown I, Horvath I, Moreno R, Gilbert T, Crowley J, Calabria P, Allocco D, Dawkins K

March 20, 2015 | 10.4244/EIJY15M01_01

One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study

Thomas M, Birkemeyer R, Schwimmbeck P, Legrand V, Moreno R, Briguori C, Werner N, Bramucci E, Ungi I, Richardt G, Underwood P, Dawkins K

March 20, 2015 | 10.4244/EIJY15M01_07

Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study

Meredith I, Worthley S, Whitbourn R, Antonis P, Montarello J, Newcomb A, Lockwood S, Haratani N, Allocco D, Dawkins K

March 20, 2014 | 10.4244/EIJV9I11A216

The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy

Farooq V, Girasis C, Magro M, Onuma Y, Morel M, Heo J, Garcia-Garcia H, Kappetein AP, van den Brand M, Holmes DR, Mack M, Feldman T, Colombo A, Stahle E, James S, Carrié D, Fournial G, Van Es G-A, Dawkins K, Mohr F, Morice M, Serruys P

December 27, 2013 | 10.4244/EIJV9I8A170

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Meredith I, Verheye S, Weissman N, Barragan P, Scott D, Valdés Chávarri M, West N, Kelbæk H, Whitbourn R, Walters D, Kubica J, Thuesen L, Masotti M, Banning A, Sjogren I, Stables R, Allocco D, Dawkins K

July 26, 2013 | 10.4244/EIJV9I3A52

The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy

March 22, 2013 | 10.4244/EIJV8I11A196

Boston Scientific Lotus valve

Meredith I, Hood K, Haratani N, Allocco D, Dawkins K

September 30, 2012 | 10.4244/EIJV8SQA12

Vasomotor function and re-endothelialisation after implantation of biodegradable abluminal polymer coated paclitaxel-eluting stents in rabbit iliac arteries: a time-course study

Nakamura T, Winsor-Hines D, Yin X, Sushkova N, Chen J, King III S, Chronos N, Eppihimer M, Huibregtse B, Dawkins K, Hou D

August 24, 2012 | 10.4244/EIJV8I4A77

Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials

Kereiakes D, Popma J, Cannon L, Kandzari D, Kimmelstiel C, Meredith I, Teirstein P, Verheye S, Allocco D, Dawkins K, Stone GW

June 27, 2012 | 10.4244/EIJV8I2A32

Comparison of the SYNERGY with the PROMUS (XIENCE V) and bare metal and polymer-only Element control stents in porcine coronary arteries

Wilson G, Huibregtse B, Pennington D, Dawkins K

June 27, 2012 | 10.4244/EIJV8I2A39

Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS)

Morice M, Feldman T, Mack M, Stahle E, Holmes DR, Colombo A, Morel M, van den Brand M, Serruys P, Mohr F, Carrié D, Fournial G, James S, Leadley K, Dawkins K, Kappetein AP

October 28, 2011 | 10.4244/EIJV7I6A109

Latest news

NEW ISSUE

"Shocktopics” with intravascular lithotripsy, bioprosthetic valve fracture, myocardial fibrosis in TAVI...

Reimaged models and angiograms showing CO March 17, 2020

March 20, 2020

JAA

New ahead of print: Infolding of self expanding valve during transcatheter aortic valve implantation

Nandhakumar Vasu et al

March 24, 2020

Editorial

Bioresorbable scaffolds and STEMI: an ideal setting, but still vacant

Christian Spaulding

March 20, 2020

Trials Book

New Update: CULPRIT, NOBEL, IVUS-XPL, SAFARI-STEMI

(supported by Biotronik)

February 14, 2020

Guidance Papers

Guidelines, consensus & position papers

April 9, 2019

Editorial

Defining procedural MI - does it matter (spoiler alert - it does!)

Gregg W Stone

March 24, 2020

JAA

This week’s JAA’s: QFR in severe AS & Infection control for TAVI

March 24, 2020

Keith D. Dawkins

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke